India’s Biocon Buys 70 Percent Stake In German Drug Firm AxiCorp GmbH
This article was originally published in PharmAsia News
Executive Summary
BANGALORE, India - India's Biocon Ltd. said it paid €30 million ($43.5 million) to buy a 70 percent stake in German drug firm AxiCorp GmbH to expand marketing and distribution of products such as injectable insulin, generics, biosimilars and biologics in Europe
You may also be interested in...
India’s Biocon Breaks Into Global Top 10 Biotech List
MUMBAI - Indian biotech firm Biocon has emerged as the seventh largest employer among the top global biotech companies, according to a survey released by Med Ad News
India’s Biocon Breaks Into Global Top 10 Biotech List
MUMBAI - Indian biotech firm Biocon has emerged as the seventh largest employer among the top global biotech companies, according to a survey released by Med Ad News
India's Biocon Issues One-For-One Bonus Shares, Says Acquisitions, New Drug Development To Drive Earnings
BANGALORE, India - India's largest biotechnology drug firm Biocon said clinical trials for diabetes, psorasis, arthritis and cancer drugs are progressing and it plans to launch a new cardio-diabetes division to focus on brand building for its statin Statix (atorvastatin)